A few companies have started the season off strong. Let’s examine the top trending stocks investors are excited about. The post Top Trending Stocks to Buy...
Customers upset with the Rogan decision are reportedly receiving an automated message when the company used to offer live customer support.
Shares of Taysha Gene Therapies were down more than 10 percent after a patient's death marred positive interim data for the company’s experimental gene therapy treatment for Sandhoff...
Global smartphone shipments had already begun to shrink ahead of 2020, though two years of a pandemic and the resulting supply chain and chip constraints certainly...
I could spend hours discussing early-stage startup operations and community-based marketing, but deal flow is my blind spot.
Can these penny stocks push up next month? The post Best Penny Stocks to Buy Next Month? Check These 3 Out appeared first on Penny Stocks...
The controversy highlights that podcasts are likely more important to the streaming giant than music.
MINA/USD has collapsed from $6.7 to $2.06 since November 11, and the current price stands at $2.26. World’s lightest blockchain Mina is the world’s lightest blockchain,...
Wedgewood Partners’ CIO says Visa Inc (NYSE: V) is a promising reopening stock a day after the financial services company reported record revenue for its fiscal...
The markets lower as it continues one of the worst sell-offs since March 2020. The post Stock Market Today: Dow Jones, S&P 500 Slides; Apple Surges...
Check these three penny stocks out for your watchlist today The post Why These 3 Penny Stocks Are Exploding Today appeared first on Penny Stocks to...
Disney's return of parades and castle shows may be the final return-to-normal move in the (sort of) post-Covid era that brings guests back.
Mondelez, producer of brands ranging from Chips Ahoy to Triscuits, says the pandemic will keep people at home and snacking, inflation notwithstanding.
Climate models from the 1970s and 80s stand up incredibly well when compared with actual warming trends.
Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis...